Clinical trials: sponsored by Samsung Medical Center
Hypothyroidism
Non-immune Related Hypothyroidism in Iodine Sufficient Area
Background: Autoimmune hypothyroidism has been regarded as the most common cause of primary hypothyroidism in iodine sufficient area and has relationship with excess iodine induced hypothyroidism.
- Trial name
- NCT03180892
- Testing
- The investigators did not apply any intervention for the participants.
- Volunteers
- 6,564 people
- Sponsor
- Samsung Medical Center
Marfan Syndrome
Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
Marfan syndrome (MFS) is an inherited disorder of connective tissue with morbidity and mortality from aortic dilatation and dissection.
- Trial name
- NCT01715207
- Testing
- Aliskiren, Atenolol
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Prostate Cancer With Radical Prostatectomy
The Efficacy and Safety of Udenafil in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy
This study evaluates the efficacy and safety of Udenafil dosed once a day in patients with erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
- Trial name
- DA8159_EDP_IIT (NCT03142542)
- Testing
- ZYDENA TAB.75mg(Udenafil 75mg)
- Volunteers
- 99 people
- Sponsor
- Samsung Medical Center
Breast Cancer
Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer
The purpose of this study is to investigate and analyse genomic profiles in patient with breast cancer who failed standard treatment, refractory and young breast cancer.
- Trial name
- NCT02597179
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- Samsung Medical Center
Breast Cancer
Prognostic Relevance of Biological Subtype in Breast Cancer
Recently, the investigators face "on the edges" for treatment decision to decide adjuvant systemic treatment, especially for patients who show discordance between stage and tumor biology.
- Trial name
- NCT02063906
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Samsung Medical Center
Advanced Breast Cancer
Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer
The primary goal of therapy in patients with metastatic breast cancer is palliation and prolongation of life with quality. Although there are no randomized trials comparing chemotherapy with supportive care in women with…
- Trial name
- NCT00561119
- Testing
- gemcitabine , paclitaxel
- Where
- 15 sites in South Korea
- Volunteers
- 326 people
- Sponsor
- Samsung Medical Center
Breast Cancer
Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer
Gene expression studies have identified at least four molecularly distinct subtypes of breast cancer including two biologically distinct ER-positive subtypes of breast cancer: luminal A and luminal B (with luminal B tumors having…
- Trial name
- NCT01273415
- Where
- South Korea
- Volunteers
- 1,070 people
- Sponsor
- Samsung Medical Center
First Line Chemotherapy, Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel
Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma
Until today, the 5-FU/cisplatin combination is the reference regimen with 30-45% response rates, which is most commonly used to treat patients with metastatic, recurrent or locally advanced, unresectable squamous cell carcinoma…
- Conditions
- First Line Chemotherapy, Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel, Advanced or Recurrent Esophageal Squamous Cell Carcinoma
- Trial name
- XP versus XT (NCT00816634)
- Testing
- Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Samsung Medical Center
Metastatic Breast Cancer, Estrogen Receptor Positive Tumor
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women
Fulvestrant is an ER antagonist with no agonist effects, which binds, blocks and degrades the ER. Fulvestrant is comparable to third-generation aromatase inhibitors in terms of efficacy and tolerability for patients who have…
- Conditions
- Metastatic Breast Cancer, Estrogen Receptor Positive Tumor, Breast Cancer Nos Premenopausal
- Trial name
- FLAG (NCT01266213)
- Testing
- Fulvestrant plus Goserelin, Anastrozole plus Goserelin, Goserelin
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Samsung Medical Center
Breast Cancer, Docetaxel Chemotherapy
A Trial of Evonail® Solution for Prevention or Treatment of Onycholysis
This study is a prospective randomized controlled study of EVONAIL® solution for prevention or treatment of onycholysis in patients with breast cancer receiving docetaxel chemotherapy.
- Trial name
- NCT02670603
- Testing
- EVONAIL® solution
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Metastatic Colorectal Cancer
Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer
Colorectal cancer (CRC) accounts for 10% to 15% of all cancers and is the second leading cause of cancer deaths in Western countries.
- Trial name
- NCT02060669
- Testing
- Xeloda
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Samsung Medical Center
Breast Cancer
Young Breast Cancer Cohort Study
This study is prospective cohort study to investigate and identify comprehensively the clinicopathological features and long-term outcome of young breast cancer (YBC).
- Trial name
- YBC (NCT03131089)
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Samsung Medical Center
Stroke, Acute, Progressing Stroke
Safety and Efficacy of Therapeutic INduced HYPERTENSION in Acute Non-cardioembolic Ischemic Stroke (SETIN-HYPERTENSION)
The purpose of this study is to evaluate the safety and efficacy of the induced hypertension using phenylephrine in patients with noncardioembolic ischemic stroke.
- Trial name
- NCT01600235
- Testing
- Phenylephrine
- Where
- South Korea
- Volunteers
- 170 people
- Sponsor
- Samsung Medical Center
Biliary Tract Cancer
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Phase II Study of Refametinib, a MEK inhibitor, as second-line treatment in advanced biliary tract adenocarcinoma
- Trial name
- NCT02346032
- Testing
- refametinib
- Volunteers
- 4 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients
To explore biomarkers predictive of clinical response to sorafenib in unresectable hepatocellular carcinoma using the Prometheus Platform To analyze expression and activation status of receptor tyrosine kinases in signal…
- Trial name
- NCT01481805
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Stroke
MR-based Collateral Imaging to Predict Response to Endovascular Treatment of Stroke (FAST-COLL Study)
Based on the results of recent randomized controlled trials, current international guidelines recommend the initiation of endovascular treatment within 6 hours of symptom onset for acute ischemic stroke.
- Trial name
- NCT02668627
- Testing
- Endovascular treatment
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Samsung Medical Center
Carotid Stenosis
Clopidogrel Resistance and Embolism in Carotid Artery Stenting
The purpose of this study is to evaluate the efficacy and safety of the ticlopidine + ginko biloba compared to clopidogrel in clopidogrel resistant patients undergoing carotid artery stent placement.
- Trial name
- CRECAS (NCT02133989)
- Testing
- Ticlopidine + Ginko biloba, Clopidogrel
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- Samsung Medical Center
Moyamoya Disease, Intracranial Atherosclerotic Stroke
Moyamoya Disease Biomarkers in Patients With Intracranial Atherosclerotic Stroke
The aim of this study is to investigate the proportion of patients with moyamoya disease among the patients who were diagnosed as having intracranial atherosclerotic stroke.
- Conditions
- Moyamoya Disease, Intracranial Atherosclerotic Stroke, Intracranial Steno-occlusive Disease
- Trial name
- NCT02074111
- Where
- South Korea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma
pazopanib_NCRCC,Ph2 STUDY
Recent advances in understanding the biology and genetics of renal cell carcinoma (RCC) have led to major therapeutic implications.
- Trial name
- NCT01538238
- Testing
- pazopanib
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Samsung Medical Center
Stroke, Ischemic
The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) Study
The objectives of this study was to test hypothesis that ischemic stroke patients having moderate to severe persistent neurologic deficit will have better outcomes with intravenous transplantation of autologous mesenchymal stem…
- Trial name
- STARTING-2 (NCT01716481)
- Testing
- Mesenchymal stem cell
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center